Content created by Office of Infectious Disease and HIV/AIDS Policy (OIDP)
The cross-agency work group focused on implementing the Viral Hepatitis National Strategic Plan 2021-2025 (Viral Hepatitis Implementation Working Group) continues to meet regularly to monitor progress, strategize about overcoming obstacles, and identify and capitalize on new opportunities or address emerging needs. In addition, the Viral Hepatitis Implementation Working Group develops progress reports, highlighting select accomplishments in implementing the National Strategic Plan.
2023 Progress Report
The National Strategic Plan sets five goals and has eight core and eight disparities indicators, with annual, 2025, and 2030 quantitative targets, to measure progress toward the goals. This is the second progress report on the National Strategic Plan. The table below presents overall progress for each indicator measure toward 2025 targets. The 2023 status is based on 2021 surveillance data.
- 2023 Progress Report At a Glance
- For more details, read the full 2023 Progress Report for the Viral Hepatitis National Strategic Plan 2021-2025
Overall Progress on National Strategic Plan Indicators
Met or exceeded current annual target
Moving toward annual target, but annual target was not fully met
Annual target was not met and has not changed or moved away from annual target
Data not available
| Indicator | 2023 Status |
|---|---|
| Goal 1: Prevent New Viral Hepatitis Infections | |
| 1. Reduce new hepatitis A infections by 40% by 2025 | |
| 2. Reduce acute hepatitis B infections by 20% by 2025 | |
| 3. Reduce acute hepatitis C infections by 20% by 2025 | |
| 4. Increase rate of hepatitis B “birth dose” vaccination to 75% by 2025a | |
| Goal 2: Improve Viral Hepatitis–Related Health Outcomes of People with Viral Hepatitis | |
| 5. Increase proportion of people with hepatitis B infection aware of their infection to 50% by 2025b | |
| 6. Reduce rate of hepatitis B–related deaths by 20% by 2025 | |
| 7. Increase proportion of people who have cleared hepatitis C infection to 58% by 2025 | |
| 8. Reduce hepatitis C–related deaths by 25% by 2025 | |
| Goal 3: Reduce Viral Hepatitis–Related Disparities and Health Inequities | |
| 9. Reduce acute hepatitis B infections among people who inject drugs by 25% by 2025 | |
| 10. Increase proportion of people with hepatitis B infection aware of their infection among Asian and Pacific Islander people to 50% by 2025 | |
| 11a. Reduce rate of hepatitis B–related deaths among Asian and Pacific Islander people by 25% by 2025 | |
| 11b. Reduce rate of hepatitis B–related deaths among non-Hispanic Black people by 25% by 2025 | |
| 12a. Reduce acute hepatitis C infections among people who inject drugs by 25% by 2025 | |
| 12b. Reduce acute hepatitis C infections among American Indian and Alaska Native people by 25% by 2025 | |
| 13a. Reduce rate of hepatitis C–related deaths among American Indian and Alaska Native people by 30% by 2025 | |
| 13b. Reduce rate of hepatitis C–related deaths among non-Hispanic Black people by 30% by 2025 | |
- 2021-2022 Viral Hepatitis Action Plan Progress Report*
- 2020 Viral Hepatitis Action Plan Progress Report (2.9 MB)*
- 2018-2019 Viral Hepatitis Action Plan Progress Report (5.8 MB)*
- 2017 Viral Hepatitis Action Plan Progress Report (1.6 MB)
- 2016 Viral Hepatitis Action Plan Progress Report (1.1 MB)
- 2015 Viral Hepatitis Action Plan Progress Report (1.1 MB)
- 2014 Viral Hepatitis Action Plan Progress Report (2.2 MB)
- 2013 Viral Hepatitis Action Plan Progress Report (655 KB)
- 2012 Viral Hepatitis Action Plan Progress Report (818 KB)
- 2011 Viral Hepatitis Action Plan Progress Report (787 KB)
Stay Informed
Stay Informed
Subscribe to email updates for the latest information about viral hepatitis.
* People using assistive technology may not be able to fully access information in these files. For assistance, contact the HHS Office of Infectious Disease and HIV/AIDS Policy by emailing Ann.Aikin@hhs.gov.